IntroductIon
Coronary heart disease accounts for approximately one-third of global deaths in recent years. 1 Similarly, cardiovascular diseases (CVD) are leading causes of death in Taiwan. 2 Low-density lipoprotein cholesterol (LDL-C) has been identified as one of the major modifiable risk factors of CVD. [3] [4] [5] [6] Fundamental lifestyle changes and several medications have been recommended to control blood cholesterol. Among all medicines, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, or statins, are a major drug class given their efficacy in reducing LDL-C. [7] [8] [9] On average, administration of statins helps to lower LDL-C by 20% to 60%. 6 10-12 In addition to lowering cholesterol, statins are shown to decrease risk of coronary events by 18%, myocardial infarction by 24% and heart failure by 35%. 13 Statins are recommended by major clinical guidelines as the drug of choice for reduction of blood lipids to prevent CVD globally. [7] [8] [9] In the USA, the 2013 'American College of Cardiology/American Heart Association (ACC/ AHA)' Guideline 7 recommends that patients with CVD history or with CVD risk factors, such as high LDL-C and diabetes, receive moderate-to-high-intensity statins. 7 The European Society of Cardiology (ESC) and Open Access UK's National Institute for Health and Care Excellence guidelines suggest prescribing statins with the highest recommended dose in order to reach target cholesterol level. 8 9 In Taiwan, prescribing of statins generally follows drug coverage requirements under the National Health Insurance (NHI), which recommends the use of statins in patients with CVD risk factors or with high cholesterol level. 14 It is reasonable for patients to be prescribed with a statin plus another lipid-lowering agent if triglyceride level is also high.
Statins have been the most commonly prescribed drugs in the world in recent decades; their global market sales reached around $28.5 billion in 2014. 15 16 Previous studies from the USA and Europe showed substantial increases in statin users, prescription rates and prescribed daily doses of statins over time. [17] [18] [19] Likewise in Taiwan statin users grew from 190 000 in 2000 to nearly 600 000 in 2004, and drug expenditures and prescription doses escalated over 200% and 400%, respectively. 20 21 Based on the updated clinical guidelines and related evidence, use of the more intense statin therapy for secondary prevention and initiation of statins for primary prevention among patients who are at a higher risk of CVD has increased. 7 22 While statins have been the mainstay of cholesterol control and heart attack and stroke prevention for the past 20 years, the treatment paradigm may change with the availability of new drugs that target an enzyme called PCSK9 (PCSK9 inhibitors) in 2015. 23 However, little is known about recent statin use in Taiwan. 24 The aims of this study were to examine the prescribing patterns of statins over the last decade and to investigate the association between patients' medical history and drug selection of statin. Our study results can be used to improve rational use of statins in light of clinical recommendations. At present, PCSK9 inhibitors are not yet reimbursed by Taiwan's National Health Insurance (NHI). Our findings also provide baseline trends that can be used to examine how new PCSK9 inhibitors, once become available under the NHI, impact the market of cholesterol medications.
Methods
This study used claims data from the 2010 Longitudinal Health Insurance Database (LHID2010) derived from Taiwan's National Health Insurance Research Database (NHIRD), which compiles data of over 99% of people (around 23 million residents) in Taiwan. 25 LHID2010 contains all the original claims data of 1 million beneficiaries randomly sampled in year 2010 from the NHIRD. LHID2010 data are overall representative of all beneficiaries as no significant differences were found in the distributions of age, gender and average premium rate between individuals in the LHID2010 and the original NHIRD data sets. 26 The data set provides information on demographic characteristics, diseases diagnosis, treatment and related medical expenditures, and orders of ambulatory and inpatient care.
New statin users in each year during 2002-2011 were included and formed the study population of each year. New statin users were defined as those who had not taken any statin in the previous years prior to the index date. The index date of every patient in each study year was defined as the date of the first statin prescription in the year. For patients in every study year, only the first prescription that contained any statins was examined in this study. We used the Anatomical Therapeutic Chemical (ATC) codes 27 to identify patients who were prescribed any statins, including atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin. Monotherapy was defined as only one statin prescription on the index date, while combination therapy was defined by prescriptions for a statin plus other lipid-lowering drugs (such as fibrates) on the index date.
The main measure was yearly prescription rate of each statin among new statin users. Yearly prescription rate of a specific statin agent was calculated by the number of patients prescribed with the specific statin agent divided by the total number of new statin users in the year. We also calculated the yearly prescription rates of monotherapy/combined statin therapy and of different levels of intensity.
Statins were grouped into three levels of intensity according to their ability to lower LDL-C based on the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol 7 and Rosenson et al
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:
(1) high-intensity statins: atorvastatin ≧40 mg/day, rosuvastatin ≧20 mg/day and simvastatin ≧80 mg/day; (2) moderate-intensity statins: 10 mg/day ≦ atorvastatin <40 mg/day, 5 mg/day ≦ rosuvastatin <20 mg/day, 20 mg/day ≦ simvastatin <80 mg/ day, pravastatin ≧ 40 mg/day, lovastatin ≧40 mg/ day and fluvastatin ≧80 mg/day; and (3) low-intensity statins: atorvastatin <10 mg/day, rosuvastatin <5 mg/day, simvastatin <20 mg/day, pravastatin <40 mg/day, lovastatin <40 mg/day and fluvastatin <80 mg/day. Daily dose can be calculated from the information of what statin has been prescribed, its dosage form, frequency and number of pills within a certain period.
All new statin users were also classified based on whether they have disease histories of interest (including coronary events, cerebrovascular events, myopathy, liver injury and diabetes) or not. 30 The first three diagnoses relate to use of statin for CVD prevention and the latter two diagnoses related to the potential adverse effects of statins. We anticipate a higher percentage use of higher intensity statins among patients with CVD or diabetes. Myopathy 31 32 and liver toxicity 32 33 (increasing the enzymes aspartate transaminase and alanine transaminase) are two of the main dose-dependent side effects associated with statin use. 34 35 Open Access Therefore, it was anticipated that a higher percentage of patients with a history of these diseases would use low-intensity statins. Individuals were defined as having a history of the following diseases if they have a diagnosis within certain years prior to the given year: coronary event (3 years), cerebrovascular event (5 years), diabetes (1 year), myopathy (3 years) and liver injury (3 years). 30 36-38 This study applied descriptive statistics to report the prescription rates of each statin and used χ 2 test to investigate the associations between patients' disease history and statin drug selection. All analyses were carried out with SAS V. 9 Figure 1 shows the prescribing trends of statins over time.
During the study period, almost all patients were prescribed with a single statin when they first started (98.6% in 2002 and 94.0% in 2011). Only 1.4% of patients were prescribed with combination therapy in 2002, with fibrates accounting for 83.3% of the combination therapies. Use of combination therapy increased to 6.0% in 2011, with ezetimibe accounting for 66.2% of combined lipid-lowering drugs.
In 2002, prescription rates of low-intensity and moderate-intensity statins were similar (51.0% and 49.0%). However, prescription rates of moderate-intensity statins gradually increased to 71.0% in 2011, while prescription rates of low-intensity statins gradually decreased to 27.3% in 2011. In comparison, use of high-intensity statins remained low (under 2.1%) during the study period (figure 2). Table 3 and figure 3 show the prescription rates of statins among new statin users with/without history of specific diseases. Compared with those without CVD, higher percentages of people with history of coronary events or cerebrovascular events were prescribed atorvastatin (51.4% vs 35.6% and 42.7% vs 35.4%, respectively, in 2011) or rosuvastatin (32.5% vs 19.3% and 27.5% vs 19.1%, respectively, in 2011). In patients with myopathy or liver injury history, prescription rates of different statins did not vary greatly through the study period compared with those without history of the diseases. Similarly, prescription rates of different statins did not vary greatly between people with and without diabetes. Table 4 indicates the findings of the associations between certain disease history and prescription of highor moderate-intensity statins. Patients with CVD history were more likely to be prescribed moderate-intensity or high-intensity statins (OR ranged from 1.52 to 2.83 during the study period, p<0.05). Similar results were found in patients with cerebrovascular events history compared with those without (OR ranged from 1.17 to 1.88 during 2006-2011, p<0.05). However, patients with diabetes history were less likely to be prescribed moderate-intensity or high-intensity statins compared with patients without diabetes history (OR ranged from 0.83 to 0.90 during 2007-2011, p<0.05). No substantial differences in prescribing patterns of statins were observed throughout the study period in groups with versus without history of myopathy or liver injury (table 4) .
dIscussIon
This longitudinal study of a national cohort found that more than half statin users were initiated on a single statin, with atorvastatin being the most commonly prescribed statin over the last decade in Taiwan. Use of moderate-intensity statins increased by 22.0% between 2002 and 2011, while use of high-intensity statins remained low. Lastly, patients with history of coronary events or cerebrovascular events were more likely to be prescribed higher intensity statins compared with those without. Prescribing of higher intensity statins was not greater among people with diabetes compared with those without during 2007-2011. This difference was also not seen in people with versus without history of myopathy or liver injury.
From 2002 to 2011, initiation of statins increased over time, similar to studies from other countries. 18 39-41 Initiation of statins in Taiwan has grown from 0.6% in 2002 to 1.8% in 2011. Our findings are similar to studies from other countries that found similar utilisation rates and increasing trend over time. For instance, a study used data of Italian local pharmacies and demonstrated incidence of statin exposure growing from 0.36% in 1994 to 0.74% in 2003. 42 Another study, which was also conducted in Italy, exhibited yearly incidence of statin Unit: number of patient. Afib, atrial fibrillation; CeVD, cerebrovascular diseases; CKD, chronic kidney diseases; CLD, chronic liver diseases; COPD, chronic obstructive pulmonary disease; IHD, ischaemic heart disease; PVD, peripheral vascular diseases.
Open Access 40 Our study found that atorvastatin had the highest prescription rate in Taiwan throughout the entire study. It was first introduced into Taiwan's market in 2000 and its market share surged to surpass other agents of the same drug class since the first study year. 21 In other countries, atorvastatin has also been one of the most commonly used statins. 39 40 43 The popularity of atorvastatin might be attributed to favourable research results suggesting its clinical benefits in preventing major coronary events 44 as well as marketing strategies of the pharmaceutical company. 45 When examining trends of different statins, it was noted that trends of atorvastatin and simvastatin exhibited opposite directions (figure 1). Since both statins were moderate-to-high potency agents, their similar potency may be a reason for the substitution observed. (1) high-intensity statins: atorvastatin ≧40 mg/day, rosuvastatin ≧20 mg/day and simvastatin ≧80 mg/day; (2) moderate-intensity statins: 10 mg/day ≦ atorvastatin <40 mg/day, 5 mg/day ≦ rosuvastatin <20 mg/ day, 20 mg/day ≦ simvastatin <80 mg/day, pravastatin ≧ 40 mg/day, lovastatin ≧40 mg/day and fluvastatin ≧80 mg/day; and (3) low-intensity statins: atorvastatin <10 mg/day, rosuvastatin <5 mg/day, simvastatin <20 mg/day, pravastatin <40 mg/day, lovastatin <40 mg/day and fluvastatin <80 mg/day. ACC/AHA, American College of Cardiology/American Heart Association; LDL-C, low-density lipoprotein cholesterol. Table 3 Continued
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Another high-potency statin-rosuvastatin-manifested an increase in prescription rates since its market entry at 2005. The growth in use of atorvastatin, simvastatin (+/-ezetimibe) and rosuvastatin suggests treatment trending towards use of high-potency or moderate-to-high-intensity statin therapy, which is aligned with major clinical guidelines. [7] [8] [9] The majority of statin regimen stayed within the moderate-intensity range rather than high-intensity therapy, which remained less than 5% during the study period. In a study from USA, relatively lower percentage (approximately 20% of total statin use) of high-intensity statin therapy was reported among adults ≧40 years old during 2002-2013. 47 In comparison, our study reveals substantially low use of high-intensity statin, suggesting that there is room for improving rational use of statins in Taiwan.
Few statin users initiated with combination therapy overall. Use of combined lipid-lowering agents shifted from fibrates (83.3% in 2002) to ezetimibe (66.2% in 2011). Ezetimibe entered Taiwan's market under the National Insurance coverage in 2006 as a combination drug with simvastatin (tradename Vytorin). High uptake of ezetimibe products might be associated with the evidence that ezetimibe plus simvastatin is more effective in lowering LDL-C than simvastatin alone. 48 49 Our findings demonstrated an association between having a history of CVD and high-intensity or moderate-intensity statin use. Similarly other studies have reported that patients with CVD histories were prescribed statins with higher intensity or doses. 19 50 Use of statins among these individuals might have been appropriately influenced by clinical guidelines and related evidence suggesting more intensive statin therapy reduces cardiovascular events in patients with prior CVD. 22 While diabetes has been viewed as a coronary risk equivalent, 51 we did not find greater use of higher intensity statins among those with diabetes. A possible explanation might include the accumulating evidence suggesting the association between statin use and increasing risk of diabetes 52 53 and the deterioration of glucose control in patients receiving higher intensity statin regimens. 54 Appropriateness of statin use among diabetes needs further investigation. Interestingly, we did not find different patterns of statin use between those with and without history of myopathy or liver diseases. This finding suggests that these side effects might not be of a primary concern when prescribing statin therapy in Taiwan.
This study contributes to the literature by examining the prescribing patterns of statins during 2002-2011 in Taiwan, including statin choices among patients with certain medical histories. Despite these strengths, it does have limitations. First, our analysis was based on claims data, which do not contain patients' biochemical test data (such as level of LDL-C), so we could not assess prescription patterns by disease severity. Second, this study only examined statin use among new users; we did not assess switches between statins. Further research is needed to Individuals were defined as having a history of the following diseases if they have a diagnosis within certain years prior to the given year: coronary event (3 years), cerebrovascular event (5 years), diabetes (1 year), myopathy (3 years) and liver injury (3 years).
NA, not available. Open Access address these gaps. As new PCSK9 inhibitors become available on Taiwan's NHI, our findings provide baseline trends that can be used in a future study to examine how new PCSK9 inhibitors impact the market of cholesterol medications. Open Access :
(1) high-intensity statins: atorvastatin 40 mg/day, rosuvastatin 20 mg/day and simvastatin 80 mg/day; (2) moderate-intensity statins: 10 mg/day atorvastatin < 40?mg/day, 5 mg/day rosuvastatin < 20 mg/day, 20 mg/day simvastatin < 80 mg/day, pravastatin 40 mg/day, lovastatin 40 mg/day and fluvastatin 80 mg/day; and (3) low-intensity statins: atorvastatin <10 mg/day, rosuvastatin <5 mg/day, simvastatin <20 mg/day, pravastatin <40 mg/day, lovastatin <40 mg/day and fluvastatin <80 mg/ day. Individuals were defined as having a history of the following diseases if they have a diagnosis within certain years prior to the given year: coronary event (3 years), cerebrovascular event (5 years), diabetes (1 year), myopathy (3 years) and liver injury (3 years). ACC/AHA, American College of Cardiology/American Heart Association; LDL-C, low-density lipoprotein cholesterol.
Open Access conclusIon Our study with national cohorts of new statin users in each year during 2002-2011 in Taiwan found that the majority of new users initiated on statin monotherapy, and atorvastatin was the most commonly prescribed statin. While patients with history of CVD were more likely to be prescribed higher intensity statins compared with those without, which is consistent with clinical guidelines, such difference was not found comparing those with and without diabetes. Appropriateness of statin use among diabetes needs further investigation.
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